Comparative evaluation of the safety and efficacy of etoricoxib and diclofenac on the upper gastrointestinal tract in patients with osteoarthrosis and rheumatoid arthritis (the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program)


Cite item

Full Text

Abstract

The review gives and analyzes the data of a number of studies evaluating the safety and efficacy of nonsteroidal anti-inflammatory drugs on the upper gastrointestinal tract. Particular emphasis is laid on the results of the multinational etoricoxib and diclofenac arthritis long-term (MEDAL) study program. The randomized MEDAL study has shown that etoricoxib has more benefits than diclofenac.

About the authors

L I Alekseyeva

Research Institute of Rheumatology, Russian Academy of Medical Sciences, Moscow

Research Institute of Rheumatology, Russian Academy of Medical Sciences, Moscow

References

  1. Vane J. R. Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs. Nat. New Biol. 1971; 231: 232-235.
  2. DuBois R. N., Abramson S. B., Crofford L. et al. Cyclooxygenase in biology and medicine. FASEB J. 1998; 12: 1063-1073.
  3. Blanco F. J., Guitian R., Moreno J. et al. Effect of anti-inflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. J. Rheumatol. 1999; 26: 1366-1373.
  4. Hawkey C. J. COX-2 inhibitors. Lancet 1999; 353: 307-314.
  5. Brooks P. M., Day R. O. Nonsteroidal anti-inflammatory drugs: Differences and similarities. N. Engl. J. Med. 1991; 324: 1716-1725.
  6. Furst D. E. Are there differences among nonsteroidal anti-inflammatory drugs? Comparing acetylated salicylates, nonacetylated salicylates, and nonacetylated nonsteroidal anti-inflammatory drugs. Arthr. and Rheum. 1994; 37: 1-9.
  7. Luong C. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nat. Struct. Biol. 1996; 3: 927- 933.
  8. FitzGerald G. A., Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med. 2001; 345: 433-442.
  9. Hinz B., Brune K. Cyclooxygenase-2 - ten years later. J. Pharmacol. Exp. Ther. 2002; 300: 367-375.
  10. Flower R. J. The development of COX2 inhibitors. Nat. Rev. Drug Discov. 2003; 2: 179-191.
  11. Brune K., Lanz R. Pharmacokinetics of non-steroidal anti-inflammatory drugs. In: Bonta I. L. et al., eds. Handbook of inflammation. Amsterdam: Elsevier Science Publishers; 1985; vol. 5: The Pharmacology of inflammation: 413-449.
  12. Rodrigues A. D. et al. Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers. Drug Metab. Dispos. 2003; 31: 224-232.
  13. Насонов Е. Л. Нестероидные противовоспалительные препараты (Перспективы применения в медицине). М.; 2000.
  14. Peura D. A. Prevention of nonsteroidal antiinflammatory drug-associated gastrointestinal symptoms and ulcer complications. Am. J. Med. 2004; 117 (suppl. 5A): S63-S71.
  15. Lanas A., Perez-Aisa M. A., Feu F. et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am. J. Gastroenterol. 2005; 100: 1685-1693.
  16. Wilcox C. M., Allison J., Benzuly K. et al. Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin. Clin. Gastroenterol. Hepatol. 2006; 4: 1082-1089.
  17. Laine L., Margolis J., Brown K. Use of GI protective agents and COX-2 selective inhibitors in 14394624 U. S. patients taking NSAIDs. Gastroenterology 2004; 126 (suppl. 2): A36- A37.
  18. Chan F. K., Chung S. C., Sucn B. Y. et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N. Engl. J. Med. 2001; 344: 967-973.
  19. Lai K. C., Lam S. K., Chu K. M. et al. Lansoprazole for the prevention of recurrences of ulcer Complications from long-term low-doSc aspirin use. N. Engl. J. Med. 2002; 346: 2033- 2038.
  20. Laine L., Curtis S. P., Cryer B. et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2007; 369: 465- 473.
  21. Larkai E. N., Smith J. L., Lidsky M. D. et al. Dyspepsia in NS A ID users: the size of the problem. J. Clin. Castroenterol. 1989; 11: 158-162.
  22. Scheiman I. M. Unmet needs in non-steroidal anti-inflammatory drug-induced upper gastrointestinal diseases. Drugs 2006; 66 (suppl. 1): 15-21.
  23. Laine L., Maller E. S., Yu C. et al. Ulcer formation with low-dose enteric-Coated aspirin and the effect of COX-2 Selective inhibition: a double-blind trial Gastroenterdogy 2004; 127: 395-402.
  24. Goldstein J. L., Lowry S. C., Lanza F. L. et al. The impact of low-dose aspirin on endoscopie gastric and duodenal ulcer rates in user of a non-Selective non-steroidal anti-inflammatory drug or a Cyclo-oxygcnase-2-Selective inhibitor. Aliment. Pharmacol. Ther. 2006; 23: 1489-1498.
  25. Goldstein J. L. AiSenberg J., Berger M., Dodge W. E. Effects of Concomitant aspirin (81 mg ql) on incidence of gastric and/ or duodenal ulcers in healthy subjects taking celecoxib or naproxen: a randomized, placebo-controlled trial. Castroenterology 2006; 130 (suppl. 2): A81.
  26. Schnitzer T. J., Burmester C. R., Myslcr E. et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised Controlled trial. Lancet 2004; 364: 665-674.
  27. Singh G., Fort J. G., Goldstein J. L. et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients; SUCCESS-1 Study. Am. J. Med. 2006; 119: 255-266.
  28. Rahme E., Bardou M., Dasgupta K. et al. Gastrointestinal effects of rofecoxib and celecoxib versus NSAlDs among patients on low dose aspirin. Castroenterology 2004; 126 (suppl. 2): Al-2.
  29. Cannon C. P., Curtis S. P., FitzGerald G. A. et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised Comparison. Lancet 2006; 368: 1771- 1781.
  30. Cannon C. P., Curtis S. P., Bolognese J. A., Laine L. Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofcnac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib vs. diclofcnac in patients with ostcoarthritis and rheumatoid arthritis. Am. Heart J. 2006; 1S2: 237-245.
  31. Laine L., Wogen J., Yu H. Gastrointestinal healthcare resource utilization with chronic use of COX-2 Specific inhibitors vs. traditional NSAIDs. Castroenterology 2003; 125: 389- 395.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies